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A B S T R A C T
Objectives: The objectives for this study were to determine the prevalence of use, safety and efﬁcacy of
different preparations of rescue medication used for prolonged seizures in children in the community
and to use the information gained to inform good practice within the network.
Methods: For all children in the EPIC area who had been prescribed epilepsy rescuemedication for use in
the community a questionnaire was completed by the clinician for each child relating to rescue
medication prescribed, the epilepsy syndrome and seizure type. A questionnaire was also completed by
the carers about their experience of the use of rescue medication in their child.
Results: A total of 203 paediatrician questionnaires were returned and 190 parent/carer questionnaires
were returned. Buccal Midazolam was the most popular rescue medication (Buccal Midazolam 110,
Rectal Diazepam 85, Paraldehyde 8).
Over 80% of the children had a community care plan in place. 90% of carers recalled receiving
instruction/training in the administration of rescue medication. The majority (73%) of carers perceived
Buccal Midazolam and Rectal Diazepam to be effective in preventing hospital admission.
Conclusion: BuccalMidazolam in itspropriety formis therescuemedicationmost commonlyprescribedby
EPIC epilepsypaediatricians. Itwas felt by families tobe the safest (least side effects reported) and themost
effective (most likelytoterminateseizures)of therescuemedications.Childrenwithsevereepilepsybeneﬁt
fromtheuseofrescuemedicationsandthenumberofhospitaladmissionsforprolongedseizures isreduced.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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1. Buccal Midazolam is as effective and as safe as Rectal Diazepam
for children presenting to hospital with acute prolonged
seizures
2. Small studies have found that Buccal Midazolam is preferred by
parents and is as efﬁcacious are Rectal Diazepam.
3. Most reported studies have used the intravenous preparation of
midazolam given by the buccal or nasal route.
What this study adds
1. The proprietary form of Buccal Midazolam was felt to be
efﬁcacious and most acceptable to families and is the com-
monest preparation prescribed.* Corresponding author. Tel.: +44 1492 807503; fax: +44 1492 807503.
E-mail address: Val.Klimach@cd-tr.wales.nhs.uk.
1 EPIC is a group of paediatric neurologists, lead secondary care paediatricians for
epilepsy and paediatric epilepsy specialist nurses for Mersey region, North Wales,
Cheshire, Shrewsbury and Swansea.
1059-1311/$ – see front matter  2008 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2008.12.0022. Childrenwith severe epilepsy and their families beneﬁt from the
use of rescue medication in the community in that the number
of hospital admissions for prolonged seizures is reduced.
1. Introduction
The management of prolonged seizures in the community is an
important aspect in the care of children with severe epilepsy in
view of the mortality and morbidity which can be associated with
convulsive status epilepticus [1,2].
Children who have epilepsy and who have had prolonged
seizures are the group usually prescribed rescuemedication and in
this study this was the case. Only children with epilepsy were
included, not those with prolonged febrile seizures.
Rectal Diazepam, and more recently, intranasal and Buccal
Midazolam are the rescue medications usually used in a
community setting for prolonged convulsive seizures. A recent
multicentre randomised control trial on the safety and efﬁcacy of
Buccal Midazolam versus Rectal Diazepam for the emergency
treatment of seizures in children concluded that BuccalMidazolamvier Ltd. All rights reserved.
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presenting to hospital with acute prolonged seizures [3].
In this study the intravenous preparation was used which
poses practical problems for use in the community such as in
school and respite care since there is a glass vial to open prior to
administration.
In a previous randomised trial Buccal Midazolam was also
found to be at least as effective as Rectal Diazepam in the acute
treatment of seizures in a special residential centre for children
with epilepsy, a setting with on site medical and nursing staff [4].
Both of the aforementioned studies provide useful information
especially in a setting with medical and nursing staff present.
Two small studies have addressed the use of buccal and
intranasal midazolam by parents in the community and found it to
be preferred by parents and as efﬁcacious as Rectal Diazepam [5,6].
Again both studies used the intravenous preparation.
Seizures in the community do not always take place in the home
with the parents present. The successfulmanagement of prolonged
seizures in the community requires that the epilepsy paediatrician
and specialist epilepsy nurse address other issues, in particular the
support of school and respite care staff as well as the parent with
regard to the use of rescue medication.
EPIC is a group of Paediatric Neurologists, lead secondary care
paediatricians for epilepsy (hospital and community based) and
paediatric epilepsy specialist nurses forMersey region,NorthWales,
West Cheshire, Shrewsbury and more recently Swansea who meet
regularly for the purposes of networking, education and developing
shared good practice relating to paediatric epilepsy management.
The members of the EPIC group agreed that for reasons of
personal dignity and social appropriateness for the child (espe-
cially teenagers) and ease of administration, especially for
wheelchair users, that Buccal Midazolam is to be preferred for
use of prolonged seizures in children in the community than the
long standing practice of using Rectal Diazepam.
The use of glass vials as for the intravenous preparation in
residential social services respite facilities and schools may be
prohibitive and particularly on outings and so for practical reasons a
number of paediatricians opted for the use of a proprietary ready to
administer preparation despite the lack of clear evidence of its
effectiveness in the literature. Anecdotally this preparation is felt to
be effective but this study aims to address this and other questions
relating to the use of rescue medication in a community setting in
children within the geographical area covered by the EPIC group.
2. Methods
1. Children with epilepsy in the EPIC area (Mersey, North Wales,
West Cheshire, Swansea and part of Shropshire) who have been
prescribed Buccal Midazolam or Rectal Diazepam for use at
home, school and respite care were identiﬁed via lead epilepsy
consultant and epilepsy nurse lists for all members of EPIC.
2. Questionnaires were completed by the Clinician (Paediatrician
or Epilepsy Nurse) for each child relating to medication, the
epilepsy syndrome, type of seizures, medication preparation
prescribed and dose, and to enquire whether a care plan is in
place for its community use.
3. Questionnaires were sent to parents to complete about their
experience of use of rescue medication in their child. In some
cases the paediatric epilepsy nurse administered the ques-
tionnaire to families at home or in the clinic situation.
3. Results
A total of 203 paediatrician questionnaires were administered
and returned.A total of 190 parent/carer questionnaires were returned from
203 sent out to parents well known to their paediatricians (which
is probably the reason for the excellent response rate of 93%). For
the 190 parent/carer questionnaires there was a paediatrician
questionnaire for the corresponding child. The remaining 13
paediatrician questionnaires were not accompanied by a ques-
tionnaire completed by the child’s carers.
3.1. Epilepsy syndromes and seizure types
According to the responses on the paediatrician questionnaire,
over half of the children had symptomatic epilepsy (57%). Sixteen
percent had idiopathic generalised epilepsies, 10% idiopathic focal
epilepsies, 4% West syndrome, 2% Lennox Gastaut syndrome, 1
child had Landau-Kleffner syndrome and for 11% the epilepsy
syndrome was not known or not stated.
A variety of seizure typeswere reported, the commonest type of
seizure among the 379 reported being generalised clonic, tonic or
tonic clonic (50%). Eighteen percent of the seizure types reported
were absences (typical or atypical), 17% focal, 13% myoclonic, 2%
atonic and no reﬂex seizures were reported.
Children in this study frequently had more than one seizure
type with only around a third having only one seizure type (36%).
Forty-two percent of children had 2 seizure types, 17% had 3, 4%
had 4 and 2% had 5 seizure types.
3.2. Types of rescue medication in use
The paediatricians reported that 51% of the children were
currently receiving Buccal Midazolam as the sole rescue medica-
tion with 38% receiving Rectal Diazepam as the sole rescue
medication. 3% were receiving nasal midazolam, 1% rectal
paraldehyde and the remaining 7% were receiving combinations
of these. In some areas there has been a delay in the changeover
from diazepam to midazolam pending discussion with the local
authority legal departmentswho need to agree to indemnify carers
at school and respite facilities employed in Education and Social
Services (personal communication with EPIC members).
Parents were asked about other medications prescribed in the
past year and different from that currently being prescribed. Fifty-
six of the 68 who answered responded that Rectal Diazepam had
previously been used (82%). There has been a recent change in
paediatrician prescribing from Rectal Diazepam to Buccal Mid-
azolam.
The majority of current prescriptions (95%) were the proprie-
tary buccal preparation rather than IV preparation at 1.1%. Ten
milligrams was the dose most commonly prescribed (54%). 13% of
prescriptions were for 7.5 mg, 16% were for 5 mg and 3% were for
2.5 mg. A variety of other doses (between 0.2 mg and 12.5 mg)
were prescribed in 4% of children and 10% did not state the dose
prescribed.
For those children receiving Rectal Diazepam 56% were
receiving a dose of 5 mg and 25% a dose of 10 mg.When calculated
on a weight basis the doses of Rectal Diazepam varied widely
above and below the recommended 0.5 mg/(kg dose)1.
3.3. Care plans for administration of rescue medication in the
community
89% of paediatricians and 79% of parents/carers reported that a
rescuemedication care planwas in place for rescuemedication use
in the community (home, school and respite care). Of those care
plans in place (n = 151) 89% of parents reported that the care plans
were in date (had been prepared or updated within the past year)
Care plans are of course essential for schools and respite facilities
many of whomwill not administer the medication without a valid
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placements.
89% (of 190) parents/carers recalled receiving instruction/
training in the administration of rescue medication. They reported
that trainingwas received from a variety of sources, predominately
nursing staff (53% from an epilepsy specialist nurse, 27% from a
paediatric ward nurse and 10% from a community or school nurse).
3.4. Test doses of rescue medication
38% of families reported that rescue medication had either not
been administered in the emergency situation prior to its
prescription (29%) or they could not remember (9%) and these
families were asked whether a test dose had been administered on
the ward. Whilst only 12% recalled a test dose of diazepam, 61%
recalled a test dose of midazolam.
For paraldehyde, none of the 4 children whose parents
answered this question reported that a test dose had been given.
The much higher level of test doses for Buccal Midazolam may
be related to itsmore recent introduction and hence perhaps better
recall, or possibly the lack of clear objective evidence as to whether
a test dose is needed.
3.5. Use of rescue medication in the community
Following prescription of rescue medication 75% of the families
reported that they had needed to use it, 21% had not and 4% could
not recall this. Whilst 41% reported that it had been administered
1–3 times in the previous year, 16% reported that they had used it
4–6 times, 9% had used it 7–9 times and 19% reported that rescue
medication had been administered 10 or more times.
3.6. How well does rescue medication work
Thirty-six percent of families reported that Rectal Diazepam
‘‘always worked’’ in stopping seizures. 43% that it ‘‘usually
worked’’, 15% that it ‘‘rarely worked’’ and 6% that it never worked.
The corresponding responses for Buccal Midazolam were 55%
‘‘always’’, 31% ‘‘usually’’, 7% ‘‘rarely’’ and 7% ‘‘never’’. The families of
the 9 children for whom paraldehyde had been used responded
that it ‘‘always worked’’ in 4 cases, ‘‘usually’’ in 1 case, ‘‘rarely’’ in 2
cases and ‘‘never worked’’ in 2 cases.
3.7. Side effects of rescue medication
Parents/carers were asked whether side effects which cause
them concern had occurred and 16% reported that they had. They
were asked to give a brief description of the side effects of concern.
Thirteen were reported with Rectal Diazepam, 4 with Buccal
Midazolam, 6when combinations of rescuemedications were used.
The commonest side effect reported was drowsiness followed by
respiratory difﬁculties, seven cases of respiratory depression were
reportedwith diazepam and onewithmidazolam (‘‘choking’’) and 2
with a combination of Rectal Diazepam and Buccal Midazolam.
3.8. Does rescue medication prevent hospital admission
Thirty percent of the 142 parents responding to this question
reported that hospital admission was ‘‘always’’ averted when
rescue medication was used in the community for prolonged
seizures, 43% that it was ‘‘usually’’, 10% ‘‘rarely’’ and 11% ‘‘never’’.
4. Discussion
Evidence for the use of rescue medication for prolonged
epileptic seizures in hospital and residential specialist settings hasbeen gathered [3,4] but to date only small studies have looked at its
usefulness in a community setting [5,6].
The study reported here looked at the current clinical practice
within a paediatric epilepsy network and the views of the families
using the rescue medication were sought as described.
Studies looking at community settings need to take into account
rescuemedicationuse in schools and social services respite facilities
which, of course, requiresnotonlyparentalacceptancebut also clear
explanation to local authorities including, for example, the lack of a
product licence for Buccal Midazolam.
For paediatricians working in a community setting it is very
clear that if rescuemedication is to be used by families, schools and
in respite care settings then the preparation must be practically
easy to administer, careful written instructions (care plans) and
training must be given (as well as advice whenever needed). This
aspect of care seems to be well addressed by the EPIC network
clinicians.
The children prescribed rescue medication have severe,
predominately symptomatic epilepsy with a variety of seizure
types. Of the 379 seizure types recorded on the questionnaire
responses half were tonic clonic or tonic clonic seizures which are
dramatic and easily recognisable, for the carer who can usually
identify the beginning and end of the seizure, time it and be clear
about when to administer rescue medication.
The paediatricians reported on current prescriptions, the
parents were also asked about other rescue medications used in
the previous year and for community use there has been a shift
from Rectal Diazepam to Buccal Midazolam which is mainly used
in its proprietary form rather than the intravenous preparation
being used by the buccal route.
The doses of Rectal Diazepam prescribed varied enormously
when calculated according to weight. The doses of proprietary
BuccalMidazolamweremore standardised at 2.5 mg, 5 mg, 7.5 mg
and 10 mg for speciﬁc ages as recommended by the manufacturer.
The occasional prescription of a dose outside this recommendation
can be clearly explained in the care plan. This emphasises the
importance of clarity and ease of administration in emergency
situations in the community.
The issue of whether or not to give test doses for Buccal
Midazolam has been clariﬁed a little in that reported side effects
were uncommon and no parent reported respiratory arrest
requiring resuscitation or hospitalisation. However the question-
naire did not speciﬁcally ask this and perhaps should have in
retrospect so that clearer guidance could have been given.
Three quarters of the children prescribed rescue medication for
community use had required at least one dose in the previous year
with almost a ﬁfth having required more than 10 doses. These
children clearly had epilepsy which was not controlled by their
regular antiepileptic drugs and this is not surprising in view of the
high prevalence of severe epilepsy syndromes in this group. It is
encouraging that the majority of the children in this study avoid
hospital admissions by the use of rescue medication for prolonged
seizures and do not seem to suffer excessive adverse effects of
concern to their carers. Although hospital admissions have been
reduced it is clear that dialogue also needs to take place with the
ambulance services who are involved in the transfer of children
with status epilepticus to hospital. This is to be addressed at an
EPIC network meeting.
5. Conclusions
Buccal Midazolam in its proprietary from is the rescue
medication most commonly prescribed by epilepsy paediatricians
in the EPIC network.
Almost two thirds of children who have not received
benzodiapine rescue medication previously are given a test dose
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light of the small number of reported signiﬁcant side effects with
Buccal Midazolam.
Of the rescue medications in use Buccal Midazolam was felt to
be the safest (least side effects reported) and the most effective
(most likely to terminate seizures).
Children with severe epilepsy and their families beneﬁt from
the use of rescue medication in that the number of hospital
admissions for prolonged seizures is reduced.
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